A Protein Silencing Switch by Ligand-induced Proteasome-targeting Intrabodies

Journal of Molecular Biology

Volumn 374, Issue 3, 2007, Pages 641-654

  Melchionna, Teresa ^a,b   Cattaneo, Antonino ^a,c  

^a SISSA   (Italy)

^b Lay Line Genomics SpA   (Italy)

^c EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

intracellular antibodies; protein knock down; protein silencing; suicide intrabodies; targeted degradation

Indexed keywords

I KAPPA B ALPHA; NEUTRALIZING ANTIBODY; PROTEASOME; UBIQUITIN;

ARTICLE; CATALYSIS; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SUICIDE INTRABODY TECHNOLOGY;

EID: 35548937288     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.09.053     Document Type: Article

References (44)

1. Biocca S., and Cattaneo A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol. 5 (1995) 248-252
2. Biocca S., Neuberger M.S., and Cattaneo A. Expression and targeting of intracellular antibodies in mammalian cells. EMBO J. 9 (1990) 101-108
3. Cattaneo A., and Biocca S. The selection of intracellular antibodies. Trends Biotechnol. 17 (1999) 115-121
4. Cattaneo A., and Biocca S. Intracellular Antibodies: Development and Application. In: Cattaneo A., and Biocca S. (Eds). Chapter: Assembly, folding and stability of intracellular antibodies (1997), Springer-Verlag, New York 110-112
5. Lobato M.N., and Rabbitts T.H. Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol. Med. 9 (2003) 390-396
6. Visintin M., Tse E., Axelson H., Rabbitts T.H., and Cattaneo A. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc. Natl Acad. Sci. USA 96 (1999) 11723-11728
7. Weissman A.M. Themes and variations on ubiquitylation. Nature Rev. Mol. Cell Biol. 2 (2001) 169-178
8. Zhou P., Bogacki R., McReynolds L., and Howley P.M. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol. Cell 6 (2000) 751-756
9. Sakamoto K.M., Kim K.B., Kumagai A., Mercurio F., Crews C.M., and Deshaies R.J. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98 (2001) 8554-8559
10. Karin M., and Ben Neriah Y. Phosphorylation meets ubiquitination: the control of NF- [kappa]B activity. Annu. Rev. Immunol. 18 (2000) 621-663
11. Tse E., Lobato M.N., Forster A., Tanaka T., Chung G.T., and Rabbitts T.H. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J. Mol. Biol. 317 (2002) 85-94
12. Visintin M., Settanni G., Maritan A., Graziosi S., Marks J.D., and Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 317 (2002) 73-83
13. Vascotto F., Campagna M., Visintin M., Cattaneo A., and Burrone O.R. Effects of intrabodies specific for rotavirus NSP5 during the virus replicative cycle. J. Gen. Virol. 85 (2004) 3285-3290
14. Martineau P., Jones P., and Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J. Mol. Biol. 280 (1998) 117-127
15. Osborn L., Kunkel S., and Nabel G.J. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl Acad. Sci. USA 86 (1989) 2336-2340
16. Sun S.C., Ganchi P.A., Ballard D.W., and Greene W.C. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 259 (1993) 1912-1915
17. Preuss U., Biernat J., Mandelkow E.M., and Mandelkow E. The 'jaws' model of tau-microtubule interaction examined in CHO cells. J. Cell Sci. 110 (1997) 789-800
18. Palombella V.J., Rando O.J., Goldberg A.L., and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78 (1994) 773-785
19. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., and Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl Acad. Sci. USA 96 (1999) 10403-10410
20. Yaron A., Hatzubai A., Davis M., Lavon I., Amit S., Manning A.M., et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 396 (1998) 590-594
21. Alkalay I., Yaron A., Hatzubai A., Orian A., Ciechanover A., and Ben Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 92 (1995) 10599-10603
22. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., and Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14 (1995) 2876-2883
23. Baldi L., Brown K., Franzoso G., and Siebenlist U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J. Biol. Chem. 271 (1996) 376-379
24. Zhang J., Zheng N., and Zhou P. Exploring the functional complexity of cellular proteins by protein knockout. Proc. Natl Acad. Sci. USA 100 (2003) 14127-14132
25. Zhou P. Targeted protein degradation. Curr. Opin. Chem. Biol. 9 (2005) 51-55
26. Matsuzawa S., Cuddy M., Fukushima T., and Reed J.C. Method for targeting protein destruction by using a ubiquitin-independent, proteasome-mediated degradation pathway. Proc. Natl Acad. Sci. USA 102 (2005) 14982-14987
27. Sibler A.P., Courtete J., Muller C.D., Zeder-Lutz G., and Weiss E. Extended half-life upon binding of destabilized intrabodies allows specific detection of antigen in mammalian cells. FEBS J. 272 (2005) 2878-2891
28. Jacobson R.H., Zhang X.J., DuBose R.F., and Matthews B.W. Three-dimensional structure of beta-galactosidase from E. coli. Nature 369 (1994) 761-766
29. Willey R.L., Maldarelli F., Martin M.A., and Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 66 (1992) 7193-7200
30. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
31. Verma R., and Deshaies R.J. A proteasome howdunit: the case of the missing signal. Cell 101 (2000) 341-344
32. David D.C., Layfield R., Serpell L., Narain Y., Goedert M., and Spillantini M.G. Proteasomal degradation of tau protein. J. Neurochem. 83 (2002) 176-185
33. Shimura H., Miura-Shimura Y., and Kosik K.S. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem. 279 (2004) 17957-17962
34. Petrucelli L., Dickson D., Kehoe K., Taylor J., Snyder H., Grover A., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13 (2004) 703-714
35. Shimura H., Schwartz D., Gygi S.P., and Kosik K.S. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem. 279 (2004) 4869-4876
36. Schulman B.A., Carrano A.C., Jeffrey P.D., Bowen Z., Kinnucan E.R., Finnin M.S., et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 408 (2000) 381-386
37. Wu G., Xu G., Schulman B.A., Jeffrey P.D., Harper J.W., and Pavletich N.P. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol. Cell 11 (2003) 1445-1456
38. Petroski M.D., and Deshaies R.J. Context of multiubiquitin chain attachment influences the rate of Sic1 degradation. Mol. Cell 11 (2003) 1435-1444
39. Schweers O., Schonbrunn-Hanebeck E., Marx A., and Mandelkow E. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J. Biol. Chem. 269 (1994) 24290-42907
40. Fasulo L., Ugolini G., Visintin M., Bradbury A., Brancolini C., Verzillo V., et al. The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J. Neurochem. 75 (2000) 624-633
41. Tavladoraki P., Benvenuto E., Trinca S., De Martinis D., Cattaneo A., and Galeffi P. Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature 366 (1993) 469-472
42. Esmaeli-Azad B., McCarty J.H., and Feinstein S.C. Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J. Cell Sci. 107 (1994) 869-879
43. Kilmartin J.V., Wright B., and Milstein C. Rat monoclonal antitubulin antibodies derived by using a new nonsecreting rat cell line. J. Cell Biol. 93 (1982) 576-582
44. Novak M., Jakes R., Edwards P.C., Milstein C., and Wischik C.M. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc. Natl Acad. Sci. USA 88 (1991) 5837-5841